SYSTEMATIC REVIEW article
Front. Med.
Sec. Pulmonary Medicine
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1640027
Sarcopenia in End-Stage Lung Disease patients: A systematic review and Meta-Analysis
Provisionally accepted
- The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Sarcopenia is usually an age-related disease in the elderly, which also affects patients with end-stage lung disease (ELD), such as chronic obstructive pulmonary disease, interstitial lung disease, and pulmonary hypertension, significantly affects disease progression and clinical outcomes. Currently, there are various methods for quantifying sarcopenia through muscle mass assessment. This study aimed to evaluate the prevalence of sarcopenia in patients with end-stage lung diseases using meta-analysis and to explore its influencing factors and clinical implications. A systematic search was conducted in English databases, including PubMed, Web of Science (WOS), Embase, Cochrane Library, CINAHL, and Scopus. Two researchers independently assessed study quality using the JBI Critical Appraisal Checklist for Analytical Cross Sectional Studies. Data analysis was performed using Stata 18.0 and R 4.4.3 software. The pooled prevalence of sarcopenia in ELD patients was calculated using a random-effects model, with subgroup analyses to identify sources of heterogeneity. Twenty-four cross-sectional studies involving 6,800 patients were included. The pooled prevalence of sarcopenia in ELD patients was 31.6% (95% CI: 26.5%-36.8%). Subgroup analyses revealed higher sarcopenia prevalence in patients aged ≥70 years (vs.<70 years), males (vs. Females), those diagnosed using AWGS2019 criteria (vs.other criteria), dual-energy X-ray absorptiometry (DXA) (vs. bioelectrical impedance analysis[BIA]), Asian populations (vs. European/North American populations), and COPD patients(vs.IPF/ILD patients). Sarcopenia is prevalent among patients with ELD, with its prevalence varying across different populations due to multiple influencing factors, resulting in distinct clinical outcomes. It is recommended to implement targeted intervention strategies based on these factors to reduce the incidence of sarcopenia and enhance the quality of life. Registration: CRD420251028682 (PROSPERO).
Keywords: Sarcopenia, End-Stage Lulmonary Disease, Prevalence, Systematic review, Meta-analysis
Received: 12 Jun 2025; Accepted: 18 Sep 2025.
Copyright: © 2025 Sheng, Gu, Zhu, Meijun, Cai and Zeng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Fei Zeng, zengfei@zju.edu.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.